Interleukin-6 Receptor Inhibitor Therapy Is Associated with Improved Outcomes in Patients with Severe COVID-19 Disease

Sinha, Pranay; McLaughlin, Angela; Wetzler, Lee M.; Bhadelia, Nahid; Linas, Benjamin P.; Assoumou, Sabrina A; Ieong, Michael H.; Lin, Nina; Cooper, Ellen; Brade, Karrine D.; White, Laura F.; Barlam, Tamar F.

doi:10.2139/ssrn.3627315

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They concluded that TCZ had higher efficacy if administered after 10 days from symptom onset. P Sinha et al 12 gave TCZ in 255 patients and concluded that optimal timing for administering TCZ is early during course of disease.…”

Section: Discussionmentioning

confidence: 99%

Tocilizumab as a breakthrough in the cytokine storm of COVID-19 pneumonia- Case series in the intensive care unit

Gulabani

Chauhan²,

Saxena³

2022

IJCA

View full text Add to dashboard Cite

Tocilizumab (TCZ) is a promising treatment for management of COVID-19 pneumonia amid many controversies linked to its potential benefit. The exact time for administration of the drug to avail maximum clinical benefit is still unclear. We present a case series in which three patients with severe COVID 19 (respiratory rate of more than 30/min, breathlessness and hypoxia with Spo2<92% on room air) and without any pre-existing co-morbid conditions were administered Inj TCZ intavenously based on increasing levels of inflammatory markers (CRP and IL6), worsening dyspnea and radiographic evidence of COVID-19 deterioration. They were admitted in our Intensive care unit (ICU) nearly 7-10 after symptom onset. Their inflammatory markers were raised with CRP>75 mg/dl, IL-6 > 200 pg/ml and ABG depicted falling trend in Pao2/Fio2 ratio despite adequate ventilation. These patients received TCZ nearly 9to 14 days of ICU stay after excluding secondary bacterial and fungal infections (sputum, urine and blood culture) as their inflammatory markers increased suddenly during the late phase of the disease. Their liver and kidney functions were acceptable and no neutropenia or thrombocytopenia was ensured. Their inflammatory markers improved significantly post intervention and they weaned from non-invasive ventilation, transferred from the intensive care unit to the ward and later discharged in 20-25 days from the hospital.Therefore, we would like to emphasize consideration of TCZ in worsening critically ill COVID-19 patients as a pharmacological modality even during late phase of the disease as a means to improve oxygenation, avoiding mechanical ventilation and subsequent morbidity and mortality. COVID 19 is a dynamically evolving disease and new treatment modalities at the different stages of the disease may yield benefits in certain sub-groups of patients.

show abstract

Section: Discussionmentioning

confidence: 99%